Arbutus Biopharma (ABUS) Operating Margin (2013 - 2026)

Arbutus Biopharma has disclosed Operating Margin across 14 years of filings, most recently posting 94.3% for Q1 2026.

• Operating Margin for Q1 2026 came in at 94.3%, up 155116.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.72% (up 137260.0% YoY), and the FY2025 annual result was 270.96%, up 96577.0% from the prior year.
• Operating Margin came in at 94.3% for Q1 2026 at Arbutus Biopharma, up from 503.33% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 94.3% in Q1 2026 to a low of 1636.86% in Q3 2025.
• The 5-year median for Operating Margin is 462.82% (2023), against an average of 671.9%.
• Across the five-year window, Operating Margin slumped 113838 bps in 2024 and surged 155116 bps in 2026, its largest moves.
• Arbutus Biopharma's Operating Margin stood at 361.28% in 2022, then slumped by 168 bps to 967.23% in 2023, then gained by 8 bps to 885.2% in 2024, then soared by 43 bps to 503.33% in 2025, then jumped by 119 bps to 94.3% in 2026.
• The last three Operating Margin figures came in at 94.3% (Q1 2026), 503.33% (Q4 2025), and 1636.86% (Q3 2025), per Business Quant data.